Trans Genic has joined the existing partnership between Dainippon and the University of Tokyo to research a mAb against apoptosis inhibitor of macrophages (AIM)

Dainippon Sumitomo Pharma Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Trans Genic Inc.

Japan / Tools, Services, and Manufacturing

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

University of Tokyo

Japan / Academic

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced